Withdrawal symptoms from phenytoin, carbamazepine and sodium valproate.
A prospective, double-blind, placebo-controlled investigation of possible withdrawal symptoms from phenytoin, carbamazepine and sodium valproate is reported in patients with active epilepsy, on combination therapy. There was an increase in seizures on reduction and withdrawal of carbamazepine, but there was no convincing evidence of withdrawal symptoms from any of these drugs.
Duncan
J S
JS
Institute of Neurology, National Hospital, London, UK.
Shorvon
S D
SD
Trimble
M R
MR
D000293:Adolescent; D000328:Adult; D000368:Aged; D002220:Carbamazepine / Q000009:adverse effects* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010672:Phenytoin / Q000009:adverse effects* / Q000627:therapeutic use; D011446:Prospective Studies; D013375:Substance Withdrawal Syndrome / Q000209:etiology*; D014635:Valproic Acid / Q000009:adverse effects* / Q000627:therapeutic use
D002220:Carbamazepine; D014635:Valproic Acid; D010672:Phenytoin